
## **Emmanuel Ganotakis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1482219/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrology Dialysis Transplantation, 2006, 22, 118-127.	0.4	158
2	Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort. Angiology, 2007, 58, 689-697.	0.8	133
3	Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine, 2016, 5, 198-203.	2.7	106
4	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Current Medical Research and Opinion, 2010, 26, 713-719.	0.9	93
5	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Archives of Medical Science, 2011, 5, 796-805.	0.4	72
6	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Current Medical Research and Opinion, 2011, 27, 1659-1668.	0.9	47
7	Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women. Current Vascular Pharmacology, 2011, 9, 647-657.	0.8	44
8	Impairment of anorectal function in diabetes mellitus parallels duration of disease. Diseases of the Colon and Rectum, 1999, 42, 1394-1400.	0.7	35
9	Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1122-6.	1.4	35
10	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. Current Drug Targets, 2007, 8, 483-488.	1.0	27
11	Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome. Angiology, 2012, 63, 358-366.	0.8	27
12	Losartan Affects Glomerular AKT and mTOR Phosphorylation in an Experimental Model of Type 1 Diabetic Nephropathy. Journal of Histochemistry and Cytochemistry, 2013, 61, 433-443.	1.3	26
13	Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?. Current Pharmaceutical Design, 2013, 19, 4964-4980.	0.9	15
14	Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia. Open Cardiovascular Medicine Journal, 2009, 3, 57-68.	0.6	5